Bris­tol My­er­s' next-gen im­munol­o­gy med busts Am­gen's Ote­zla in head-to-head study. Is a show­down com­ing?

In an immunology market packed with blockbuster biologics, Bristol Myers Squibb hopes that its oral drug for milder cases could carve out a lucrative foothold. Now, with its eyes set on busting Amgen’s Otezla, the drugmaker is rolling out full data from a pair of late-stage studies that bode well for its candidate.